Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2)

被引:25
|
作者
Egieyeh, Samuel [1 ]
Egieyeh, Elizabeth [2 ]
Malan, Sarel [3 ]
Christofells, Alan [4 ]
Fielding, Burtram [5 ]
机构
[1] Univ Western Cape, Sch Pharm, Pharmacol & Clin Pharm Unit, Computat Pharmacol & Cheminformat Res Grp, Cape Town, South Africa
[2] Univ Western Cape, Sch Pharm, Pharmacol & Clin Pharm Unit, Cape Town, South Africa
[3] Univ Western Cape, Sch Pharm, Pharmaceut Chem Unit, Cape Town, South Africa
[4] Univ Western Cape, South African Natl Bioinformat Inst, South African Med Res Council, Bioinformat Unit, Cape Town, South Africa
[5] Univ Western Cape, Dept Med Biosci, Mol Biol & Virol Res Lab, Cape Town, South Africa
来源
PLOS ONE | 2021年 / 16卷 / 01期
关键词
ACE2;
D O I
10.1371/journal.pone.0245258
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Drug repurposing for COVID-19 has several potential benefits including shorter development time, reduced costs and regulatory support for faster time to market for treatment that can alleviate the current pandemic. The current study used molecular docking, molecular dynamics and protein-protein interaction simulations to predict drugs from the Drug Bank that can bind to the SARS-CoV-2 spike protein interacting surface on the human angiotensin-converting enzyme 2 (hACE2) receptor. The study predicted a number of peptide-based drugs, including Sar9 Met (O2)11-Substance P and BV2, that might bind sufficiently to the hACE2 receptor to modulate the protein-protein interaction required for infection by the SARS-CoV-2 virus. Such drugs could be validated in vitro or in vivo as potential inhibitors of the interaction of SARS-CoV-2 spike protein with the human angiotensin-converting enzyme 2 (hACE2) in the airway. Exploration of the proposed and current pharmacological indications of the peptide drugs predicted as potential inhibitors of the interaction between the spike protein and hACE2 receptor revealed that some of the predicted peptide drugs have been investigated for the treatment of acute respiratory distress syndrome (ARDS), viral infection, inflammation and angioedema, and to stimulate the immune system, and potentiate antiviral agents against influenza virus. Furthermore, these predicted drug hits may be used as a basis to design new peptide or peptidomimetic drugs with better affinity and specificity for the hACE2 receptor that may prevent interaction between SARS-CoV-2 spike protein and hACE2 that is prerequisite to the infection by the SARS-CoV-2 virus.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] A strategy to optimize the peptide-based inhibitors against different mutants of the spike protein of SARS-CoV-2
    Priya, Prerna
    Basit, Abdul
    Bandyopadhyay, Pradipta
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2023, 41 (13): : 6191 - 6202
  • [2] Computational analysis of spike protein of SARS-CoV-2 (Omicron variant) for development of peptide-based therapeutics and diagnostics
    Pritam, Manisha
    Dutta, Somenath
    Medicherla, Krishna Mohan
    Kumar, Rajnish
    Singh, Satarudra Prakash
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2024, 42 (14): : 7321 - 7339
  • [3] Phytoncides could potentially inhibit the spike protein of SARS-CoV-2 variants
    Bharathi, Muruganantham
    Sivamaruthi, Bhagavathi Sundaram
    Kesika, Periyanaina
    Thangaleela, Subramanian
    Chaiyasut, Chaiyavat
    PHYTOTHERAPY RESEARCH, 2022, 36 (11) : 4020 - 4023
  • [4] In SilicoScreening of Potential Spike Glycoprotein Inhibitors of SARS-CoV-2 with Drug Repurposing Strategy
    Wei Tian-zi
    Wang Hao
    Wu Xue-qing
    Lu Yi
    Guan Sheng-hui
    Dong Feng-quan
    Dong Chen-le
    Zhu Gu-li
    Bao Yu-zhou
    Zhang Jian
    Wang Guan-yu
    Li Hai-ying
    CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2020, 26 (09) : 663 - 669
  • [5] In Silico Screening of Potential Spike Glycoprotein Inhibitors of SARS-CoV-2 with Drug Repurposing Strategy
    WEI Tian-zi
    WANG Hao
    WU Xue-qing
    LU Yi
    GUAN Sheng-hui
    DONG Feng-quan
    DONG Chen-le
    ZHU Gu-li
    BAO Yu-zhou
    ZHANG Jian
    WANG Guan-yu
    LI Hai-ying
    Chinese Journal of Integrative Medicine , 2020, (09) : 663 - 669
  • [6] In Silico Screening of Potential Spike Glycoprotein Inhibitors of SARS-CoV-2 with Drug Repurposing Strategy
    WEI Tianzi
    WANG Hao
    WU Xueqing
    LU Yi
    GUAN Shenghui
    DONG Fengquan
    DONG Chenle
    ZHU Guli
    BAO Yuzhou
    ZHANG Jian
    WANG Guanyu
    LI Haiying
    Chinese Journal of Integrative Medicine, 2020, 26 (09) : 663 - 669
  • [7] In Silico Screening of Potential Spike Glycoprotein Inhibitors of SARS-CoV-2 with Drug Repurposing Strategy
    Tian-zi Wei
    Hao Wang
    Xue-qing Wu
    Yi Lu
    Sheng-hui Guan
    Feng-quan Dong
    Chen-le Dong
    Gu-li Zhu
    Yu-zhou Bao
    Jian Zhang
    Guan-yu Wang
    Hai-ying Li
    Chinese Journal of Integrative Medicine, 2020, 26 : 663 - 669
  • [8] A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
    Gordon, David E.
    Jang, Gwendolyn M.
    Bouhaddou, Mehdi
    Xu, Jiewei
    Obernier, Kirsten
    White, Kris M.
    O'Meara, Matthew J.
    Rezelj, Veronica V.
    Guo, Jeffrey Z.
    Swaney, Danielle L.
    Tummino, Tia A.
    Huttenhain, Ruth
    Kaake, Robyn M.
    Richards, Alicia L.
    Tutuncuoglu, Beril
    Foussard, Helene
    Batra, Jyoti
    Haas, Kelsey
    Modak, Maya
    Kim, Minkyu
    Haas, Paige
    Polacco, Benjamin J.
    Braberg, Hannes
    Fabius, Jacqueline M.
    Eckhardt, Manon
    Soucheray, Margaret
    Bennett, Melanie J.
    Cakir, Merve
    McGregor, Michael J.
    Li, Qiongyu
    Meyer, Bjoern
    Roesch, Ferdinand
    Vallet, Thomas
    Mac Kain, Alice
    Miorin, Lisa
    Moreno, Elena
    Naing, Zun Zar Chi
    Zhou, Yuan
    Peng, Shiming
    Shi, Ying
    Zhang, Ziyang
    Shen, Wenqi
    Kirby, Ilsa T.
    Melnyk, James E.
    Chorba, John S.
    Lou, Kevin
    Dai, Shizhong A.
    Barrio-Hernandez, Inigo
    Memon, Danish
    Hernandez-Armenta, Claudia
    NATURE, 2020, 583 (7816) : 459 - +
  • [9] A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
    David E. Gordon
    Gwendolyn M. Jang
    Mehdi Bouhaddou
    Jiewei Xu
    Kirsten Obernier
    Kris M. White
    Matthew J. O’Meara
    Veronica V. Rezelj
    Jeffrey Z. Guo
    Danielle L. Swaney
    Tia A. Tummino
    Ruth Hüttenhain
    Robyn M. Kaake
    Alicia L. Richards
    Beril Tutuncuoglu
    Helene Foussard
    Jyoti Batra
    Kelsey Haas
    Maya Modak
    Minkyu Kim
    Paige Haas
    Benjamin J. Polacco
    Hannes Braberg
    Jacqueline M. Fabius
    Manon Eckhardt
    Margaret Soucheray
    Melanie J. Bennett
    Merve Cakir
    Michael J. McGregor
    Qiongyu Li
    Bjoern Meyer
    Ferdinand Roesch
    Thomas Vallet
    Alice Mac Kain
    Lisa Miorin
    Elena Moreno
    Zun Zar Chi Naing
    Yuan Zhou
    Shiming Peng
    Ying Shi
    Ziyang Zhang
    Wenqi Shen
    Ilsa T. Kirby
    James E. Melnyk
    John S. Chorba
    Kevin Lou
    Shizhong A. Dai
    Inigo Barrio-Hernandez
    Danish Memon
    Claudia Hernandez-Armenta
    Nature, 2020, 583 : 459 - 468
  • [10] Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein
    Feng, Siqin
    Luan, Xiaodong
    Wang, Yifei
    Wang, Hui
    Zhang, Zhiyu
    Wang, Yiyang
    Tian, Zhuang
    Liu, Meixi
    Xiao, Ying
    Zhao, Yong
    Zhou, Ruilin
    Zhang, Shuyang
    INFECTION GENETICS AND EVOLUTION, 2020, 85